Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer.

Abstract

This study evaluated the influence of positive peritoneal cytology (PPC) on the prognosis of patients with stage IA endometrial cancer, and the usefulness of adjuvant chemotherapy in their treatment. We retrospectively analyzed the data of patients with stage IA endometrial cancer admitted in our hospital between 2005 and 2015. Among 989 patients who underwent peritoneal cytology, 135 (13.7%) had PPC. Multivariate analysis extracted several independent risk factors for recurrence in stage IA patients, including those with PPC. Adjuvant chemotherapy did not cause a significant difference in the 5-year relapse-free survival rate in patients with PPC (p = 0.78). Similarly, the 5-year recurrence-free survival rate with or without chemotherapy was not different among type II cancer patients (p = 0.11). However, the baseline risk of 5-year relapse-free survival without chemotherapy in patients with PPC and type II was very low (66.7%). While PPC was an independent risk factor for recurrence in stage IA endometrial cancer, adjuvant chemotherapy did not influence the survival rate in patients with PPC. While it is controversial whether adjuvant chemotherapy should be administered in stage IA uterine cancer with only PPC as a prognostic factor, it should be considered for early-stage patients who have multiple risk factors for recurrence.

• Authors: Motoko Kanno, Mayu Yunokawa, Makoto Nakabayashi, Makiko Omi, Ai Ikki, Megumi Mizusaki, Mai Nishimura, Yusuke Shimizu, Kota Okamoto, Yuji Tanaka, Atsushi Fusegi, Sachiho Netsu, Tomoko Kurita, Yoichi Aoki, Terumi Tanigawa, Maki Matoda, Sanshiro Okamoto, Hidetaka Nomura, Kohei Omatsu, Yuko Sugiyama, Kuniko Utsugi, Nobuhiro Takeshima, Hiroyuki Kanao
• Journal: Scientific reports (Sci Rep) Vol. 12 Issue 1 Pg. 166 (01 07 2022) ISSN: 2045-2322 [Electronic] England
• PMID: 34997003 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Biopsy
• Chemotherapy, Adjuvant
• Disease Progression
• Endometrial Neoplasms (drug therapy, mortality, pathology)
• Female
• Humans
• Hysterectomy (adverse effects, mortality)
• Middle Aged
• Neoplasm Metastasis
• Neoplasm Recurrence, Local
• Neoplasm Staging
• Peritoneum (pathology)
• Predictive Value of Tests
• Progression-Free Survival
• Retrospective Studies
• Risk Assessment
• Risk Factors
• Time Factors